Sleep Apnea Syndromes
Conditions
Keywords
sleep apnea, intermittent hypoxia, regulatory T cell, autoimmunity
Brief summary
To compare the number and function of regular T cell of patients with obstructive sleep apnea (OSA) versus that of age-, gender- and BMI (body mass index)-matched controls
Detailed description
Patients with obstructive sleep apnea (OSA) experience intermittent hypoxemia and arousal during sleep due to recurrent collapse of upper airway. Epidemiologic evidence showed they were at higher risk for autoimmune diseases. The regular T cell (Treg) has a crucial role in controlling autoimmunity. In this study, 40 OSA patients and 40 age-, gender- and BMI-matched controls will be recruited. Peripheral venous blood of the participants is drawn for numeration of CD4+CD25+FoxP3+ regular T cells by flow cytometry. As well, the CD4+CD25+ regular T cells are enriched by MACS and tested for their suppressive functions on proliferation assays. Th12+ CD4+ cells are also measured.
Interventions
BIOLOGICALOSA
This study aims to compare the difference in the number and function of regulatory T cells between OSA patients and controls. The investigators will draw peripheral venous blood samples from both groups and measure the number and function of their regulatory T cells. However, some, NOT ALL, of OSA patients may receive continuous positive airway pressure (CPAP) treatment-the standard therapy for severe-to-moderate OSA. Use of CPAP is based on physician's suggestion and patients' decision, but not for this study. The devices are provided by patients themselves and its type/brand is not limited or prespecified. For those with CPAP therapy, their blood sample will be re-collected 26 weeks later to repeat measurement for subgroup analysis.
Sponsors
Taipei Veterans General Hospital, Taiwan
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. OSA patients diagnosed with a polysomnography 2. Agree to participate the study and sign informed consent
Exclusion criteria
1. Do not agree to participate the study and sign informed consent 2. Has received any treatment or OSA 3. With major comorbidities (such as a diabetes, heart disease, lung diseases, renal diseases, autoimmune diseases, but hypertension excluded) 4. History of sarcoidosis and tuberculosis 5. On treatment of steroid and immunosuppressant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number and function of regular T cells in peripheral venous blood | 0-26 week |
Secondary
| Measure | Time frame |
|---|---|
| The number of Th12+ CD4+ cells | 0-26 week |
Countries
Taiwan
Contacts
Primary ContactKun-Ta Chou, MD
Outcome results
None listed